{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:02:08Z","timestamp":1770138128201,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2020,11,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hepatic fibrosis is the major issue in chronic liver diseases such as chronic\nhepatitis C virus (HCV). The newly approved direct acting antiviral (DAA) agents such as Sofosbuvir\n(SOF) and daclatasvir (DAC) have been found to be associated with decreased fibrotic markers in\nHCV patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>This study tried to explore whether the reported antifibrotic effect of these drugs is antiviral dependent\nor drug induced.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>Hepatic fibrosis was induced by (0.5ml\/kg) CCl4 IP twice a week for six weeks. SOF (20\nmg\/kg\/d) and DAC (30 mg\/kg\/d) were added in the last four weeks of treatments. Liver functions,\nfibrotic markers such as Hyaluronic acid and metalloproteinase-9 were detected using immunoassay.\nThe expression of TNF-\u03b1\/NF-\u03baB signaling pathway as well as Bcl-2 were done using immunoassay.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>SOF and DAC exerted a potent antifibrotic effect evidenced by their activity against\nhyaluronic acid HA and metalloproteinase MMP-9 significantly (P\u22640.001). This effect was further\nproved histopathologically where liver tissues from rats treated by drugs showed marked inhibition of\ncollagen precipitation as well as inhibition of HSCs activation. This antifibrotic action was associated\nwith decreased expression of TNF-\u03b1 \/NF-\u03baB signaling pathway and induction of Bcl-2.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>SOF\/ DAC antifibrotic effect is independent of its antiviral activity. The molecular events\nassociated with this effect were the downregulation of TNF-\u03b1 \/ NF-\u03baB signaling pathway and induction\nof Bcl-2.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874467213666200116114919","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T14:35:48Z","timestamp":1579271748000},"page":"318-327","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Daclatasvir and Sofosbuvir Mitigate Hepatic Fibrosis Through Downregulation of TNF-\u03b1 \/ NF-\u03baB Signaling Pathway"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-9901","authenticated-orcid":true,"given":"Sherin","family":"Zakaria","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kaferelsheikh University, Kaferelsheikh, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa E.","family":"El-Sisi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0091270003258669","volume":"44","year":"2004","unstructured":"Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol Global Burden of Hepatitis C Working Group2004,44(1),20-29","journal-title":"J Clin Pharmacol"},{"key":"ref=2","author":"El-Zanaty F.","year":"2009","unstructured":"El-Zanaty F.; Way A.;  2009"},{"key":"ref=3","year":"2015","unstructured":"Ministry of Health and Population [Egypt], El-Zanaty and Associates\n[Egypt] and ICF International.  Egypt Health Issues Survey 2015\n(Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and\nPopulation and ICF International, 2015), 2015","journal-title":"Egypt Health Issues Survey 2015\n(Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and\nPopulation and ICF International, 2015),"},{"key":"ref=4","year":"2016","unstructured":"Hepatitis C fact sheet no 164 [updated July 2015], WHO2016","journal-title":"Hepatitis C fact sheet no 164 [updated July 2015],"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3892\/ijmm.2017.2997","volume":"40","author":"Lee J.W.","year":"2017","unstructured":"Lee J.W.; Kim Y.I.; Kim Y.; Choi M.; Min S.; Joo Y.H.; Yim S.V.; Chung N.; Grape seed proanthocyanidin inhibits inflammatory responses in hepatic stellate cells by modulating the MAPK, Akt and NF-\u03baB signaling pathways. Int J Mol Med 2017,40(1),226-234","journal-title":"Int J Mol Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.gastro.2003.11.018","volume":"126","author":"Bataller R.","year":"2004","unstructured":"Bataller R.; Paik Y.H.; Lindquist J.N.; Lemasters J.J.; Brenner D.A.; Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004,126(2),529-540","journal-title":"Gastroenterology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"9599","DOI":"10.1073\/pnas.171311298","volume":"98","author":"Gong G.","year":"2001","unstructured":"Gong G.; Waris G.; Tanveer R.; Siddiqui A.; Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001,98(17),9599-9604","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0098-2997(00)00004-2","volume":"21","author":"Poli G.","year":"2000","unstructured":"Poli G.; Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000,21(3),49-98","journal-title":"Mol Aspects Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","volume":"20","author":"Sebastiani G.","year":"2014","unstructured":"Sebastiani G.; Gkouvatsos K.; Pantopoulos K.; Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014,20(32),11033-11053","journal-title":"World J Gastroenterol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"Lawitz E.","year":"2014","unstructured":"Lawitz E.; Poordad F.F.; Pang P.S.; Hyland R.H.; Ding X.; Mo H.; Symonds W.T.; McHutchison J.G.; Membreno F.E.; Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014,383(9916),515-523","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"Sulkowski M.S.","year":"2014","unstructured":"Sulkowski M.S.; Gardiner D.F.; Rodriguez-Torres M.; Reddy K.R.; Hassanein T.; Jacobson I.; Lawitz E.; Lok A.S.; Hinestrosa F.; Thuluvath P.J.; Schwartz H.; Nelson D.R.; Everson G.T.; Eley T.; Wind-Rotolo M.; Huang S.P.; Gao M.; Hernandez D.; McPhee F.; Sherman D.; Hindes R.; Symonds W.; Pasquinelli C.; Grasela D.M.; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014,370(3),211-221","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S160593","author":"Ahmed OA","year":"2018","unstructured":"Ahmed OA; Elsebaey MA; Fouad MHA; Elashry H;  Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection 2018","journal-title":"Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/17441692.2014.984742","volume":"10","author":"Kim D.D.","year":"2015","unstructured":"Kim D.D.; Hutton D.W.; Raouf A.A.; Salama M.; Hablas A.; Seifeldin I.A.; Soliman A.S.; Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health 2015,10(3),296-317","journal-title":"Glob Public Health"},{"key":"ref=14","first-page":"12671","volume":"31","author":"Ayoub H.H.","year":"2016","unstructured":"Ayoub H.H.; Abu-Raddad L.J.; Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention. J Viral Hepat 2016,31,12671","journal-title":"J Viral Hepat"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.rmu.2017.05.005","volume":"19","author":"Salas-Villalobosa T.B.","year":"2017","unstructured":"Salas-Villalobosa T.B.; Lozano-Sep\u00falvedaa S.A.; Rinc\u00f3n-S\u00e1nchezb A.R.; Govea-Salasc M.; Rivas-Estillaa A.M.; Mechanisms involved in liver damage resolution after hepatitis C virus clearance. Medicina Universitaria 2017,19(75),100-107","journal-title":"Medicina Universitaria"},{"key":"ref=16","first-page":"1001","volume":"1","author":"Ishikawa T.","year":"2017","unstructured":"Ishikawa T.; Imai M.; Owaki T.; Sato H.; Serum Wisteria floribunda Agglutinin Positive Mac-2-Binding Protein and Fib-4 Index on the Clinical Course of Patients with Chronic Hepatitis C Receiving Daclatasvir\/Asunaprevir Therapy. Ann Digest Liver Dis 2017,1,1001","journal-title":"Ann Digest Liver Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.5009\/gnl17298","volume":"12","author":"Lee H.W.","year":"2018","unstructured":"Lee H.W.; Oh S.R.; Kim D.Y.; Jeong Y.; Kim S.; Kim B.K.; Kim S.U.; Kim D.Y.; Ahn S.H.; Han K.H.; Park J.Y.; Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. Gut Liver 2018,12(3),324-330","journal-title":"Gut Liver"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/jgh.13758","volume":"32","author":"Elsharkawy A.","year":"2017","unstructured":"Elsharkawy A.; Alem S.A.; Fouad R.; El Raziky M.; El Akel W.; Abdo M.; Tantawi O.; AbdAllah, M.; Bourliere, M.; Esmat, G. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol 2017,32(9),1624-1630","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5604\/01.3001.0010.8662","volume":"17","author":"Said M.M.","year":"2018","unstructured":"Said M.M.; Azab S.S.; Saeed N.M.; El-Demerdash E.; Antifibrotic Mechanism of Pinocembrin: Impact on Oxidative Stress, Inflammation and TGF-\u03b2\/Smad Inhibition in Rats. Ann Hepatol 2018,17(2),307-317","journal-title":"Ann Hepatol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"9409","DOI":"10.1038\/s41598-017-09797-8","volume":"7","author":"Ferreira A.C.","year":"2017","unstructured":"Ferreira A.C.; Zaverucha-do-Valle C.; Reis P.A.; Barbosa-Lima G.; Vieira Y.R.; Mattos M.; Silva P.P.; Sacramento C.; de Castro Faria Neto H.C.; Campanati L.; Tanuri A.; Br\u00fcning K.; Bozza F.A.; Bozza P.T.; Souza T.M.L.; Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. Sci Rep 2017,7(1),9409","journal-title":"Sci Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00535-015-1108-6","volume":"50","author":"Kai Y.","year":"2015","unstructured":"Kai Y.; Hikita H.; Tatsumi T.; Nakabori T.; Saito Y.; Morishita N.; Tanaka S.; Nawa T.; Oze T.; Sakamori R.; Yakushijin T.; Hiramatsu N.; Suemizu H.; Takehara T.; Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol 2015,50(11),1145-1151","journal-title":"J Gastroenterol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ajcp\/28.1.56","volume":"28","author":"Reitman S.","year":"1957","unstructured":"Reitman S.; Frankel S.; A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957,28(1),56-63","journal-title":"Am J Clin Pathol"},{"key":"ref=23","author":"Banchroft J.D.","year":"1996","unstructured":"Banchroft J.D.; Stevens A.; Turner D.R.;  Theory and practice of histological techniquesNew York 1996","journal-title":"Theory and practice of histological techniquesNew York"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"Ishak K.","year":"1995","unstructured":"Ishak K.; Baptista A.; Bianchi L.; Callea F.; De Groote J.; Gudat F.; Denk H.; Desmet V.; Korb G.; MacSween R.N.; Histological grading and staging of chronic hepatitis. J Hepatol 1995,22(6),696-699","journal-title":"J Hepatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","volume":"38","author":"Friedman S.L.","year":"2003","unstructured":"Friedman S.L.; Liver fibrosis - from bench to bedside. J Hepatol 2003,38(Suppl. 1),S38-S53","journal-title":"J Hepatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5114\/ceh.2018.78121","volume":"4","author":"Ibrahim M.A.","year":"2018","unstructured":"Ibrahim M.A.; Abdel-Aziz A.; El-Sheikh A.; Kamel M.; Khalil A.Z.; Abdelhaleem H.; Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats. Clin Exp Hepatol 2018,4(3),175-181","journal-title":"Clin Exp Hepatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jhep.2015.07.041","volume":"64","author":"Dyson J.K.","year":"2016","unstructured":"Dyson J.K.; Hutchinson J.; Harrison L.; Rotimi O.; Tiniakos D.; Foster G.R.; Aldersley M.A.; McPherson S.; Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016,64(1),234-238","journal-title":"J Hepatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"S403","DOI":"10.1016\/S0168-8278(18)31042-0","volume":"68","author":"Mazzarelli C.","year":"2018","unstructured":"Mazzarelli C.; Bruce M.; Imbert S.; Cannon M.D.; FRI-093 - Direct fibrosis markers kinetic in patients undergoing antiviral treatment with DAA for chronic hepatitis C. J Hepatol 2018,68(Suppl. 1),S403","journal-title":"J Hepatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000084626","volume":"71","author":"Reif S.","year":"2005","unstructured":"Reif S.; Somech R.; Brazovski E.; Reich R.; Belson A.; Konikoff F.M.; Kessler A.; Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005,71(2),124-130","journal-title":"Digestion"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"12928","DOI":"10.1074\/jbc.M700554200","volume":"282","author":"Han Y.P.","year":"2007","unstructured":"Han Y.P.; Yan C.; Zhou L.; Qin L.; Tsukamoto H.; A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans differentiation in the three-dimensional extracellular matrix. J Biol Chem 2007,282(17),12928-12939","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cyto.2004.11.001","volume":"29","author":"Sudo K.","year":"2005","unstructured":"Sudo K.; Yamada Y.; Moriwaki H.; Saito K.; Seishima M.; Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine 2005,29(5),236-244","journal-title":"Cytokine"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0168-8278(99)80007-5","volume":"30","author":"Knittel T.","year":"1999","unstructured":"Knittel T.; Mehde M.; Kobold D.; Saile B.; Dinter C.; Ramadori G.; Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 1999,30(1),48-60","journal-title":"J Hepatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/hep.26429","volume":"58","author":"Pradere J.P.","year":"2013","unstructured":"Pradere J.P.; Kluwe J.; De Minicis S.; Jiao J.J.; Gwak G.Y.; Dapito D.H.; Jang M.K.; Guenther N.D.; Mederacke I.; Friedman R.; Dragomir A.C.; Aloman C.; Schwabe R.F.; Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 2013,58(4),1461-1473","journal-title":"Hepatology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"Karin M.","year":"2006","unstructured":"Karin M.; Nuclear factor-kappaB in cancer development and progression. Nature 2006,441(7092),431-436","journal-title":"Nature"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"Cheung M.C.M.","year":"2016","unstructured":"Cheung M.C.M.; Walker A.J.; Hudson B.E.; Verma S.; McLauchlan J.; Mutimer D.J.; Brown A.; Gelson W.T.H.; MacDonald D.C.; Agarwal K.; Foster G.R.; Irving W.L.; HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016,65(4),741-747","journal-title":"J Hepatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jhep.2016.07.004","volume":"65","author":"Nault J.C.","year":"2016","unstructured":"Nault J.C.; Colombo M.; Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol 2016,65(4),663-665","journal-title":"J Hepatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"Reig M.","year":"2016","unstructured":"Reig M.; Mari\u00f1o Z.; Perell\u00f3 C.; I\u00f1arrairaegui M.; Ribeiro A.; Lens S.; D\u00edaz A.; Vilana R.; Darnell A.; Varela M.; Sangro B.; Calleja J.L.; Forns X.; Bruix J.; Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon free therapy. J Hepatol 2016,65(4),719-726","journal-title":"J Hepatol"},{"key":"ref=38","first-page":"776","volume":"12","author":"Robert S.","year":"2016","unstructured":"Robert S.; B., Jr The possible association between DAA treatment for HCV infection and HCC recurrence. Gastroenterol Hepatol (N Y) 2016,12(12),776-779","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/hep.29855","volume":"68","author":"Huang A.C.","year":"2018","unstructured":"Huang A.C.; Mehta N.; Dodge J.L.; Yao F.Y.; Terrault N.A.; Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018,68(2),449-461","journal-title":"Hepatology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","volume":"156","author":"Singal A.G.","year":"2019","unstructured":"Singal A.G.; Rich N.E.; Mehta N.; Branch A.; Pillai A.; Hoteit M.; Volk M.; Odewole M.; Scaglione S.; Guy J.; Said A.; Feld J.J.; John B.V.; Frenette C.; Mantry P.; Rangnekar A.S.; Oloruntoba O.; Leise M.; Jou J.H.; Bhamidimarri K.R.; Kulik L.; Tran T.; Samant H.; Dhanasekaran R.; Duarte-Rojo A.; Salgia R.; Eswaran S.; Jalal P.; Flores A.; Satapathy S.K.; Wong R.; Huang A.; Misra S.; Schwartz M.; Mitrani R.; Nakka S.; Noureddine W.; Ho C.; Konjeti V.R.; Dao A.; Nelson K.; Delarosa K.; Rahim U.; Mavuram M.; Xie J.J.; Murphy C.C.; Parikh N.D.; Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology 2019,156(6),1683-1692","journal-title":"Gastroenterology"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/178363\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/178363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:56:52Z","timestamp":1746572212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178363\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467213666200116114919","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}